Pareto Securities publishes research report revising price target to SEK 86
Hørsholm, Denmark, April 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their analysis of ExpreS2ion following the announcement that the Company will be conducting a Rights Issue. Pareto reiterated its ‘buy’ rating and reduced its target price to SEK 86 per share after incorporating the estimated dilution from the Rights Issue.The research report is available on the Analyst Reports page of ExpreS[2]ion’s investor website. The next updates from